Published in Pharma Law Weekly, January 16th, 2007
As a result of the refocusing, Biovertis will suspend its antibacterials drug discovery program.
Oxaquin, a novel antibiotic designed to combat severe, life-threatening infections, currently is in a phase I study in healthy volunteers. The topoisomerase program will reach preclinical development soon.
From its drug discovery program, Biovertis in the last years has identified a number of very promising novel targets for the development of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.